Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • SUBSCRIBE

Moderna’s RSV vaccine mRNA-1345 was more than 80% effective in a Phase 3 study 

By Brian Buntz | January 18, 2023

Moderna in the Drug Discovery & Development Pharma 50mRNA vaccine company Moderna (Nasdaq:MRNA) plans on submitting for regulatory approval for its investigational RSV mRNA-1345 vaccine after it met primary efficacy endpoints in the Phase 3 ConquerRSV study (NCT05127434).

The RSV data are “a clear positive for MRNA” and represent a good omen for upcoming mRNA Phase 3 influenza data, noted UBS in a briefing note.

MRNA shares were up 5.70% in after-hours trading, hitting $201.55.

“Importantly, we think this is a milestone for MRNA’s pipeline beyond COVID in demonstrating the competitive efficacy of mRNA vaccines,” noted UBS Eliana Merle. “We think RSV could be a meaningful opportunity with no vaccine yet approved.

UBS sees an opportunity worth more than $5 billion in RSV.

The Moderna study, enrolling roughly 37,000 adults aged 60 or older in 22 countries, tested mRNA-1345 in older adults divided into two groups. One group had two or more symptoms of RSV-associated lower respiratory tract disease (RSV-LRTD). The other had three or more symptoms.

In the study, vaccine efficacy was 83.7% against RSV-associated lower respiratory tract disease (RSV-LRTD) in participants with two or more symptoms. Vaccine efficacy was 82.4% effective in individuals with three or more symptoms.

An independent Data and Safety Monitoring Board reviewed the data in the ConquerRSV study.

Investigators found the vaccine to be generally well tolerated, identifying no safety concerns. The most common adverse events included injection site pain, fatigue, headache, myalgia and arthralgia.

The ConquerRSV study is ongoing. Moderna anticipates it will be completed by November 30, 2024.

Last November, Pfizer (NYSE:PFE) also revealed positive topline data from the Phase 3 MATISSE clinical trial for its bivalent respiratory syncytial virus (RSV) prefusion vaccine candidate.

Other companies, including Bavarian Nordic (CPH: BAVA), Janssen (NYSE:JNJ) and GSK (NYSE:GSK), are also developing RSV vaccines.

After releasing its latest data, Moderna said it would also submit manuscripts to a peer-reviewed publication. It also plans on presenting it at a scientific meeting.

Moderna intends to continue studying safety and tolerability in an ongoing study.

The company also plans to develop a respiratory combination vaccine to protect against respiratory diseases, including RSV, COVID-19 and influenza. In addition, Moderna is also developing a vaccine for the human metapneumovirus, which can cause upper and lower respiratory illness in people of all ages.

Moderna is also testing mRNA-1345 in an ongoing Phase 1 study in pediatric populations.

The company launched the pivotal trial for its RSV vaccine candidate in February 2022.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: Moderna, mRNA-1345
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • SUBSCRIBE